| Anti-Mullerian Hormone - AMH Study |
LifeQuest has recently completed the first phase of its observational study to measure levels of a hormone found in the blood called Anti-Mullerian Hormone or AMH. New research has shown that AMH may be an indicator of ovarian responsiveness. This means it may be a valuable aid in assessing fertility in women who have difficulty conceiving. There are also studies showing that levels of AMH may fluctuate during treatment for polycystic ovarian syndrome (PCOS) and may be useful as a measure of response to treatment.
Phase 1:Results: LifeQuest has now established expected age-appropriate ranges for this hormone and identified correlations with other hormone levels in women with different causes of infertility. We have also identified cut-off levels of AMH that are significantly higher in women with PCOS. Our findings were presented at the Canadian Fertility and Andrology Society Annual Meeting in Montreal in November 2009. LifeQuest now offers this test to appropriate patients as an additional method of evaluating ovarian reserve and identification of possible PCOS in women undergoing infertility investigations. Unfortunately, because AMH is still a research test, and therefore not covered by OHIP, there is an additional cost if you and your physician decide to have the test done. Phase 2:Now that we have completed the preliminary study and established expected values for different age groups, we are proceeding with investigating changes in AMH levels in women with different etiologies of infertility and in women being treated for PCOS. For more information about the work we are doing with AMH, please contact Dr. Ken Cadesky at (416) 348-9030 or Chris Clark in the Immunology Research Lab at (416) 593-4448. |
| Last Updated on Friday, 09 July 2010 18:22 |